Stock listing

NASDAQ:LNAI Lunai Bioworks Inc. Stock

Home listing (NASDAQ) of Lunai Bioworks Inc.

Follow Lunai Bioworks Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LNAI

$0.165 USD -0.071 (-30.2%)

Close on Oct 29, 2026

Past year -92.7% · daily closes, May 22, 2026 – Oct 29, 2026, adjusted for splits
Day range
$0.147 – $0.230 USDOct 29, 2026
Volume
957,123 sharesOct 29, 2026
Market cap
—Left out: price × shares is far from the company's reported size
Traded on an average day
$473,891 USDMedian day 40,400 shares · last 3 months, Jul 29, 2026 – Oct 29, 2026
Lunai Bioworks Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LNAI · Home$0.165 USD-0.071 (-30.2%)957,123$0.229$0.230$0.147$0.236Close on Oct 29, 2026

Daily closes

Last 3 months, Jul 29, 2026 – Oct 29, 2026 · NASDAQ:LNAI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.165-0.071-30.2%$0.229$0.230$0.147957,123
$0.236-0.017-6.7%$0.221$0.250$0.202622,800
$0.253-0.022-8.0%$0.258$0.270$0.240521,300
$0.275-0.020-6.8%$0.263$0.302$0.233614,600
$0.295-0.175-37.2%$0.260$0.316$0.2279,584,100
$0.470-0.048-9.3%$0.530$0.530$0.460174,300
$0.518+0.003+0.6%$0.500$0.545$0.50090,400
$0.515+0.043+9.1%$0.490$0.580$0.472216,900
$0.472-0.208-30.6%$0.695$0.695$0.462202,700
$0.680-0.146-17.7%$0.812$0.812$0.66079,900
$0.826-0.066-7.4%$0.865$0.917$0.81837,800
$0.892-0.138-13.4%$0.999$1.005$0.89269,400
$1.030-0.080-7.2%$1.090$1.090$1.01046,000
$1.110-0.120-9.8%$1.290$1.290$1.05097,200
$1.230+0.110+9.8%$1.170$1.680$0.876853,300
$1.120+0.030+2.8%$1.140$1.150$1.10014,800
$1.090-0.040-3.5%$1.190$1.190$1.08020,000
$1.130-0.010-0.9%$1.130$1.200$1.13023,600
$1.140-0.160-12.3%$1.250$1.300$1.14069,000
$1.300-0.080-5.8%$1.440$1.460$1.230124,900
$1.380-0.090-6.1%$1.540$1.600$1.37538,200
$1.470-0.300-16.9%$1.890$1.890$1.385102,200
$1.770-0.090-4.8%$1.910$1.950$1.75054,100
$1.860-0.070-3.6%$2.050$2.050$1.81041,000
$1.930-0.010-0.5%$2.000$2.202$1.90028,900
$1.940-0.200-9.3%$2.185$2.185$1.93045,000
$2.140-0.090-4.0%$2.300$2.370$2.10051,800
$2.230-0.070-3.0%$2.660$2.670$2.220211,400
$2.300-0.030-1.3%$2.390$2.432$2.23013,700
$2.330+0.055+2.4%$2.270$2.360$2.26016,700
$2.275+0.105+4.8%$2.250$2.387$2.23728,500
$2.170-0.020-0.9%$2.150$2.310$2.15030,600
$2.190+0.020+0.9%$2.190$2.250$2.10020,400
$2.170-0.210-8.8%$2.400$2.610$2.15130,700
$2.380-0.055-2.3%$2.501$2.522$2.31127,200
$2.435-0.175-6.7%$2.570$2.570$2.4353,000
$2.610+0.010+0.4%$2.640$2.730$2.55067,500
$2.600+0.210+8.8%$2.390$2.929$2.39060,800
$2.390+0.040+1.7%$2.310$2.400$2.30112,500
$2.350-0.050-2.1%$2.376$2.390$2.23044,700
$2.400+0.250+11.6%$2.150$2.490$2.15054,500
$2.150-0.125-5.5%$2.260$2.330$2.15022,600
$2.275-0.095-4.0%$2.375$2.420$2.25030,300
$2.370+0.020+0.9%$2.350$2.435$2.28035,200
$2.350-0.050-2.1%$2.490$2.498$2.34039,800
$2.400+0.200+9.1%$2.200$2.480$2.20069,800
$2.200+0.070+3.3%$2.130$2.265$2.13010,100
$2.130-0.025-1.2%$2.160$2.230$2.10034,900
$2.155-0.045-2.0%$2.250$2.280$2.15026,500
$2.200-0.020-0.9%$2.152$2.260$2.15018,600
$2.220+0.055+2.5%$2.120$2.290$2.12019,500
$2.165-0.085-3.8%$2.240$2.240$2.15020,000
$2.250+0.030+1.4%$2.250$2.300$2.16030,900
$2.220-0.020-0.9%$2.250$2.250$2.15033,700
$2.240-0.110-4.7%$2.350$2.360$2.20044,600
$2.350-0.050-2.1%$2.390$2.410$2.260218,600
$2.400+0.040+1.7%$2.330$2.473$2.33030,500
$2.360-0.050-2.1%$2.450$2.450$2.30023,200
$2.410-0.010-0.4%$2.400$2.550$2.39037,600
$2.420-0.060-2.4%$2.440$2.480$2.36056,600
$2.480-0.070-2.7%$2.510$2.750$2.371103,200
$2.550+0.160+6.7%$2.160$3.200$2.135845,200
$2.390+0.450+23.2%$2.000$3.780$1.9108,102,900
$1.940-0.080-4.0%$2.050$2.130$1.94026,500
$2.020-0.090-4.3%$2.060$2.105$2.00023,300
$2.110-0.130-5.8%$2.170$2.200$2.06015,100

Splits

1 split · NASDAQ:LNAI · every price before a split is adjusted for it

DayRatioWhat
1-for-8Consolidation
Ticker
NASDAQ:LNAI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Lunai Bioworks Inc. news

Lunai Bioworks Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 30 in all · newest Oct 22, 2026 · oldest 2025
Decks
8 decks · latest January 2026

Where Lunai Bioworks Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LNAI · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LNAIBOATSUnited StatesUSD
gettex:2Q50gettexGermanyEUR
Lang & Schwarz:A41K8PLang & SchwarzGermanyEUR
Frankfurt:2Q50FrankfurtGermanyEUR
LS Exchange:A41K8PLS ExchangeGermanyEUR
Munich:2Q50MunichGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Oct 29, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
50.6%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
1.33

Team and board

Officers

OfficerRole
David WeinsteinDirector & Chief Executive Officer
Emily DoeDirector of Machine Learning Operations
Emily SmithDirector of Machine Learning Operations
Emily WangDirector of Machine Learning Operations
Ethan DoeHead of AI Research and Development
Ethan TurnerHead of AI Research and Development
Jane WangDirector of Machine Learning Operations
Sophia DoeDirector of Machine Learning Operations
Sophia PatelDirector of Machine Learning Operations

Board

DirectorRole
David WeinsteinDirector & Chief Executive Officer
Douglas W. CalderDirector
James A. McNultyDirector
Mark A. CollinsDirector

Events

QuarterResults
Q1 2027Nov 13, 2026
Q3 2026May 14, 2026 · After close
Q2 2026Feb 17, 2026 · After close
Q1 2026Nov 17, 2025 · After close
Q4 2025Sep 29, 2025
Q3 2025May 15, 2025
Q2 2025Feb 19, 2025
Q3 2023May 12, 2023
Q2 2023Feb 27, 2023
Q3 2022May 13, 2022
All 15 quarters
QuarterResults
Q2 2022Feb 14, 2022
Q1 2022Nov 15, 2021
Quarter to Jun 30, 2021Sep 24, 2021
Quarter to Mar 31, 2021May 17, 2021
Quarter to Dec 31, 2020Feb 16, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck27 slidesJanuary 2026
Investor Presentation (January 2026)Investor deck31 slidesJanuary 2026
Investor Presentation (January 2026)Investor deck31 slidesJanuary 2026
Renovaro Biosciences — Investor Presentation (January 2024)Investor deck28 slidesJan 16, 2024
Renovaro Biosciences — Investor Presentation (August 2023)Investor deck43 slidesAug 7, 2023
Enochian Biosciences — Innate Killer Summit 2023Conference10 slidesMar 28, 2023
Enochian Biosciences — Investor Presentation (October 2022)Investor deck39 slidesOct 14, 2022
Innate Killer Summit 2022Conference17 slidesMarch 2022

Open Decks

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue52.0K0000
Cost of revenue93.5K129.1K391.4K
Gross profit-41.5K-129.1K00-391.4K
Research and development24.5K537.4K2.71M4.17M8.37M15.7M4.69M2.50M617.0K62.8K
Selling, general and administrative7.80B17.9M24.6M15.3M14.3M
Operating income-8.70M-189.0M-81.6M-38.6M-116.1M-23.4M-11.9M-11.0M-5.33M-2.40M
Depreciation and amortization93.5K129.1K121.9K113.5K123.6K123.5K108.6K71.7K18.5K14.5K
EBITDA-8.60M-188.8M-81.5M-38.4M-116.0M-23.3M-11.8M-10.9M-5.31M-2.39M
Interest expense235.1K725.7K1.01M580.3K372.8K379.6K104.3K43143.3K
Income before tax-3.56M-178.0M-88.4M-39.7M-113.4M-26.8M-11.4M-18.0M-6.42M-2.21M
Income tax1.41K1.47K034-125.3K-111.7K-64.9K
Net income-3.56M-178.0M-88.4M-39.7M-113.4M-26.7M-11.4M-18.0M-6.31M-2.14M
Earnings per share, basic-1.06-86.27-0.91-0.71-2.16-0.57-0.25-0.48-0.29-0.17
Earnings per share, diluted-1.06-86.27-0.91-0.71-2.16-0.57-0.25-0.48-0.29-0.17

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents1.71M92.7K220.5K1.87M9.17M20.7M8.70M12.3M15.6M3.94M
Short-term investments0387.9K0
Receivables1.11M1.64K
Current assets2.04M1.05M2.00M2.57M9.57M20.9M8.94M12.5M15.8M4.20M
Property, plant and equipment12.0K367.8K482.1K509.0K586.5K719.4K778.1K687.5K27.4K
Goodwill5.96M5.96M159.3M11.6M11.6M11.6M11.6M11.6M11.6M
Total assets9.94M8.23M163.1M58.3M84.6M189.6M178.1M179.9M182.5M4.52M
Accounts payable12.4M12.6M9.45M5.30M1.40M320.6K
Current liabilities18.9M29.2M30.3M11.0M6.45M1.89M1.33M1.11M873.7K2.99M
Long-term debt4.58M
Total debt1.34M10.2M3.79M5.59M7.02M7.37M
Total liabilities19.0M29.6M31.2M11.8M12.0M14.9M11.8M6.78M23.8M2.99M
Shareholders' equity-9.02M-21.3M132.0M46.5M72.6M174.7M166.3M173.1M158.7M1.53M
Shares outstanding4.62M2.22M158.5M63.7M53.0M52.2M46.5M45.3M36.2M12.4M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-5.29M-7.87M-11.0M-11.8M-15.7M-20.6M-10.5M-8.51M-4.34M-1.18M
Capital spending-1.24K-3-70.4K-29.8K-5.16K-48.9K-184.5K-716.7K-30.0K
Free cash flow-5.29M-7.87M-11.0M-11.8M-15.7M-20.7M-10.6M-9.22M-4.37M
Cash from investing543.5K-500.0K-1.26M-29.8K-5.16K-48.9K-184.5K-716.7K-575.7K-196.1K
Cash from financing6.39M8.38M10.5M4.52M4.25M32.6M7.20M6.02M16.7M5.51M
Change in cash1.62M-127.8K-1.65M-7.30M-11.5M12.0M-3.59M-3.32M11.7M3.92M

Open Financials

Cap table

Built by 6ix from Lunai Bioworks Inc.’s releases

Common shares
5,034,452
Fully diluted
5,034,452

Fully diluted

LineShares
Common shares5,034,452

Share count over time

CountShares
Nov 22, 20265,034,452
May 20, 2026

Open Cap table

Shareholders

StakeStakeSharesDateFiling
William Anderson Wittekind4.50%227KOct 13, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Sapirstein
Other companies: INmune Bio Inc. (Director · Since at least Sep 8, 2026); Cocrystal Pharma, Inc. (Chief Executive Officer · Since at least Jun 3, 2026); ZyVersa Therapeutics, Inc. (Director · Since at least Jan 5, 2023); Onconetix, Inc. (Director · Feb 23, 2022 – Sep 26, 2024 · Past); Blue Water Acquisition Corp (Director · Dec 15, 2020 – Dec 15, 2020 · Past); Marizyme, Inc. (Interim CEO, Director · Sep 10, 2020 – Mar 5, 2021 · Past); GridAI Technologies Corp. (Chairman and CEO, Director · Oct 8, 2019 – Jul 2, 2024 · Past); Hepion Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 3, 2018 · Past); RespireRx Pharmaceuticals Inc (Director · Dec 9, 2017 – Dec 9, 2017 · Past)
Director · Mar 6, 2018 – Jun 25, 2024 · Past
An Evelyn D
Other companies: Backblaze, Inc. (Director · Since at least Nov 10, 2021); Matinas BioPharma Holdings, Inc. (Director · Feb 5, 2025 – Apr 30, 2025 · Past); Zoomcar Holdings Inc (Director · Dec 28, 2023 – Dec 28, 2023 · Past); Summer Infant Inc (Director · Nov 2, 2016 – Jun 22, 2022 · Past); Hot Topic Inc (Director · Jun 14, 2007 – Jun 12, 2013 · Past); Alico, Inc. (Director · Mar 28, 2006 – Jan 13, 2010 · Past)
Director · Mar 6, 2018 – Mar 6, 2021 · Past
Carol Brosgart
Other companies: Cocrystal Pharma, Inc. (Director · Since at least Aug 12, 2026); Galmed Pharmaceuticals Ltd. (Director · Since at least Mar 18, 2026); Mirum Pharmaceuticals, Inc. (Director · Jun 4, 2021 – Jun 2, 2022 · Past); Tobira Therapeutics Inc (Director · Jul 9, 2015 – Nov 1, 2016 · Past)
Director · Dec 27, 2019 – Jun 25, 2024 · Past
James A. McNulty
Other companies: Inhibitor Therapeutics Inc. (Chief Financial Officer · Since at least Dec 13, 2022); CV Sciences, Inc. (Director · Feb 5, 2018 – Jun 16, 2020 · Past)
Director · Since at least Oct 14, 2024
Leni Boeren
Other companies: Aegon Ltd. (Member of Compensation & Human Resource Committee · Since at least Apr 29, 2026)
Director · Oct 4, 2023 – Oct 4, 2023 · Past
Samir Naji Masri
Other companies: Intra-Cellular Therapies Inc (CEO, CFO, Pres & Secretary, Director · Apr 9, 2013 – Apr 9, 2013 · Past)
See Remarks, Director · Oct 11, 2011 – Oct 11, 2011 · Past
Simon Tarsh
Other companies: Onconetix, Inc. (Director · Since at least Aug 22, 2022)
Interim CFO · Mar 11, 2024 – Nov 4, 2024 · Past
Anderson Wittekind WilliamDirector · Dec 31, 2018 – Dec 31, 2018 · Past
Avram MillerDirector · Oct 11, 2023 – Aug 23, 2024 · Past
David WeinsteinDirector & Chief Executive Officer · Since at least Oct 14, 2024
All 26 people
PersonSeat
Douglas W. CalderDirector · Since at least Nov 5, 2026
Emily DoeDirector of Machine Learning Operations · Since at least Nov 4, 2026
Emily SmithDirector of Machine Learning Operations · Since at least Nov 4, 2026
Emily WangDirector of Machine Learning Operations · Since at least Nov 4, 2026
Ethan DoeHead of AI Research and Development · Since at least Nov 4, 2026
Ethan TurnerHead of AI Research and Development · Since at least Nov 4, 2026
Henrik Gronfeldt-SorensenDirector · Oct 11, 2021 – Oct 9, 2023 · Past
Jane WangDirector of Machine Learning Operations · Since at least Nov 4, 2026
Jayne McNicolDirector · May 26, 2021 – Jun 25, 2024 · Past
Karen BrinkDirector · Feb 23, 2024 – Aug 12, 2024 · Past
Luisa PucheChief Financial Officer · Jan 7, 2019 – Feb 13, 2024 · Past
Mark A. CollinsDirector · Since at least Oct 14, 2024
Mark DybulChief Executive Officer, Director · Dec 14, 2020 – Feb 13, 2024 · Past
Rene SindlevDirector · Jul 17, 2017 – Jun 25, 2024 · Past
Sophia DoeDirector of Machine Learning Operations · Since at least Nov 4, 2026
Sophia PatelDirector of Machine Learning Operations · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Lunai Bioworks Inc.